First filed May 2021; Recruiting
The primary objective of this Phase 3 randomized, double-blind, placebo-controlled study is to test the efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity.
This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.
To Learn More Contact
US Biogen Clinical Trial Center at 866-633-4636 or by email at firstname.lastname@example.org
Global Biogen Clinical Trial Center by email at email@example.com
ClinicalTrials.gov identifier: NCT04895241